All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Recombinant Moloney murine leukemia virus (MMLV) retroviral vectors serve as efficient viral vector tools for introducing genes permanently into a wide variety of dividing cells, and provide an alternative to modify primary T cells. Creative biolabs has developed retroviral CAR vector pMMLV PSMA (HuJ591) h(BBζ), which is constructed for the engineering of T cells to target human PSMA. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-PSMA antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of Prostate cancer.
CAR Construction : Fig.1 Binding of BiJ591, scFvJ591, huJ591, and OKT-3 to human PSMA and CD3 receptors by flow cytometry. LNCaP (PSMAþ) and Jurkat (CD3þ) cells were incubated with various concentrations (0.001-300 mg/mL) of antibodies and stained with a fluorescent secondary antibody. Leconet, W., Liu, H., Guo, M., Le Lamer-Déchamps, S., Molinier, C., Kim, S., ... & Bander, N. H. (2018). Anti-PSMA/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Molecular Cancer Therapeutics, 17(9), 1927-1940. |
CAR Construction : Fig.2 Cytokine release of purified T cell in presence or not of LNCaP cells and increasing concentrations of BiJ591. Cytokine concentration was determined by cytometry-based bead assay. Leconet, W., Liu, H., Guo, M., Le Lamer-Déchamps, S., Molinier, C., Kim, S., ... & Bander, N. H. (2018). Anti-PSMA/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Molecular Cancer Therapeutics, 17(9), 1927-1940. |
CAR Construction : Fig.3 BiJ591-dependent cell lysis on PCa cell lines coincubated with human PBMCs (whole WBC population, including lymphocytes and monocytes) or purified T cells. All measurements were performed in triplicate. Leconet, W., Liu, H., Guo, M., Le Lamer-Déchamps, S., Molinier, C., Kim, S., ... & Bander, N. H. (2018). Anti-PSMA/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Molecular Cancer Therapeutics, 17(9), 1927-1940. |
CAR Construction : Fig.4 Binding of the anti-PSMA mAbs 3/A12,3/E7,3/F11,and J591 to C4-2 cells. Cells were incubated with the mAbs,washed to eliminate unbound antibody, stained with goat anti-mouse Ig-RPE as secondary antibody, andanalyzed by flow cytometry. Wolf, P., Freudenberg, N., Bühler, P., Alt, K., Schultze‐Seemann, W., Wetterauer, U., & Elsässer‐Beile, U. (2010). Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. The Prostate, 70(5), 562-569. |
CAR Construction : Fig.5 Nanoscale flow cytometry of various calibration sizing beads and in vitro generated prostate microparticles. Data are represented as mean±s.d. Biggs, C. N., Siddiqui, K. M., Al-Zahrani, A. A., Pardhan, S., Brett, S. I., Guo, Q. Q., ... & Leong, H. S. (2016). Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. Oncotarget, 7(8). |
CAR Construction : Fig.6 Specific binding of J591 to PSMA and activation of fluorescence signal after binding. Scale bar indicates 20 μm. Nakajima, T., Mitsunaga, M., Bander, N. H., Heston, W. D., Choyke, P. L., & Kobayashi, H. (2011). Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody–indocyanine green (ICG) conjugate. Bioconjugate chemistry, 22(8), 1700-1705. |
CAR Construction : J591 scFv-28ζ Fig.7 Evaluation of CAR expression. Activated T cells were transduced with g-retroviral vector and stained with anti-human IgG antibody (CAR) and CD3. Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., ... & Wolf, P. (2020). PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy-Oncolytics, 18, 226-235. |
CAR Construction : J591 scFv-28ζ Fig.8 Cytolytic activity. CAR T cells were co-cultured at the indicated E:T ratios with C4-2 cells. Cytotoxicity was determined using a cell viability assay n=6. Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., ... & Wolf, P. (2020). PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy-Oncolytics, 18, 226-235. |
CAR Construction : J591 scFv-28ζ Fig.9 Quantification of tumor size. Tumor volumes were determined on days 1, 3, 8, 15, and 22 of treatment. Shown is antitumor response in Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., ... & Wolf, P. (2020). PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy-Oncolytics, 18, 226-235. |
CAR Construction : J591 scFv-28ζ Fig.10 Cytokine release. CAR T cells were co-cultured with PSMA+ C4-2 or PSMA Du145 cells, respectively. The concentration of IFN-g was determined in the supernatant (n = 3). Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., ... & Wolf, P. (2020). PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy-Oncolytics, 18, 226-235. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PSMA (HuJ591) h(41BB-CD3ζ) CAR, pMMLV (CAR-MV-01LX272). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION